View Older Stories

May 8, 2026 07:00AM Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 14, 2026 07:02AM Kiora Pharmaceuticals publishes phase 1 retinitis pigmentosa study data

Apr 14, 2026 07:00AM Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Apr 7, 2026 07:01AM Kiora Pharmaceuticals closes $24 million private placement

Apr 7, 2026 07:00AM Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Apr 2, 2026 04:31PM Kiora Pharmaceuticals chief development officer to depart April 17

Apr 2, 2026 04:30PM Kiora Pharmaceuticals Announces Management Team Changes

Mar 25, 2026 07:02AM Kiora Pharmaceuticals reports $10.8 million loss for 2025

Mar 25, 2026 07:00AM Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Feb 19, 2026 08:30AM Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Jan 27, 2026 07:03AM Kiora Pharmaceuticals adds retinal disease expert to advisory board

Jan 27, 2026 07:00AM Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Dec 1, 2025 06:47AM Kiora Pharmaceuticals receives US patent for KIO-100 formulations

Dec 1, 2025 06:45AM Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Nov 7, 2025 06:49AM Kiora Pharmaceuticals (KPRX) Tops Q3 EPS by 1c

Nov 7, 2025 06:02AM Kiora Pharmaceuticals posts net income in Q3 amid ongoing clinical trials

Nov 7, 2025 06:00AM Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Oct 30, 2025 09:01AM Kiora Pharmaceuticals joins RARE-X Vision Consortium for rare eye diseases

Oct 15, 2025 07:00AM Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Sep 4, 2025 07:00AM Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025 07:02AM Kiora Pharmaceuticals reports Q2 2025 results with two phase 2 trials

Aug 8, 2025 07:00AM Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

Aug 7, 2025 07:00AM Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 22, 2025 08:57AM Kiora Pharmaceuticals receives patent for KIO-104 ocular treatment

Jul 22, 2025 08:55AM Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

Jun 3, 2025 07:02AM Kiora Pharmaceuticals (KPRX) and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Jun 3, 2025 07:00AM Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

May 9, 2025 07:35AM Kiora Pharmaceuticals (KPRX) Misses Q1 EPS by 52c

May 9, 2025 07:00AM Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

May 5, 2025 07:00AM Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy

Apr 4, 2025 07:00AM Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025 07:00AM Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Mar 12, 2025 07:00AM Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Feb 13, 2025 07:03AM Kiora Pharmaceuticals (KPRX) Secures U.S. Composition-of-Matter Patent Expanding Protection of KIO-104

Feb 13, 2025 07:00AM Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Feb 11, 2025 06:46AM Kiora Pharmaceuticals (KPRX) Receives Approval to Initiate KLARITY

Feb 11, 2025 06:45AM Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Nov 12, 2024 07:50AM H.C. Wainwright Reiterates Buy Rating on Kiora Pharmaceuticals (KPRX)

Nov 8, 2024 07:36AM Kiora Pharmaceuticals (KPRX) Misses Q3 EPS by 81c

Nov 8, 2024 07:00AM Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Oct 29, 2024 06:47AM Kiora Pharmaceuticals (KPRX) Receives Investigational New Drug Approval to Initiate ABACUS-2

Oct 29, 2024 06:45AM Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Sep 25, 2024 09:55AM Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 9, 2024 08:31AM Kiora Pharmaceuticals (KPRX) Misses Q2 EPS by 53c

Aug 9, 2024 07:00AM Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Aug 6, 2024 07:03AM Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Jul 30, 2024 06:48AM Kiora Pharmaceuticals (KPRX) Granted EU Orphan Medicinal Product Designation for KIO-301

Jul 30, 2024 06:45AM Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Jul 10, 2024 07:00AM Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Jul 1, 2024 06:57AM Kiora Pharmaceuticals (KPRX) Appoints Lisa Walters-Hoffert to its Board

View Older Stories